Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06772246 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate QTc Prolongation With Quizartinib in Healthy Subjects Under Rapid Acceleration of Heart Rate
A Phase 1 study, sponsored by Daiichi Sankyo.
- Completed
- Registry status
- Phase 1
- Development phase
- 70
- Enrollment target
NCT06772246 is a Phase 1 study that has completed, run by Daiichi Sankyo. The registered enrollment target is 70 participants.
The verdict
NCT06772246, a Phase 1 study, has completed, sponsored by Daiichi Sankyo.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 70 participants
- Enrollment target
Study Summary
This study will evaluate the impact of rapid acceleration in the heart rate on the QT prolongation of quizartinib.
Interventions
- OTHER Placebo
- DRUG Quizartinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2024-10-24 |
| Est. Completion | 2025-06-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06772246
The ClinicalTrials.gov registry entry for NCT06772246 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Daiichi Sankyo, which has 236 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06772246 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06772246 about?
NCT06772246 is a clinical study titled "A Study to Evaluate QTc Prolongation With Quizartinib in Healthy Subjects Under Rapid Acceleration of Heart Rate". This study will evaluate the impact of rapid acceleration in the heart rate on the QT prolongation of quizartinib.
What is the current status of trial NCT06772246?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 70 participants. The study started on 2024-10-24. Estimated completion is 2025-06-12.
What interventions are being tested in trial NCT06772246?
The interventions under investigation include: Placebo (OTHER), Quizartinib (DRUG).
Who is sponsoring clinical trial NCT06772246?
This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.